Metabolites (Jan 2023)

Single Point Insulin Sensitivity Estimator (SPISE) As a Prognostic Marker for Emerging Dysglycemia in Children with Overweight or Obesity

  • Robert Stein,
  • Florian Koutny,
  • Johannes Riedel,
  • Natascha Dörr,
  • Klara Meyer,
  • Marco Colombo,
  • Mandy Vogel,
  • Christian Heinz Anderwald,
  • Matthias Blüher,
  • Wieland Kiess,
  • Antje Körner,
  • Daniel Weghuber

DOI
https://doi.org/10.3390/metabo13010100
Journal volume & issue
Vol. 13, no. 1
p. 100

Abstract

Read online

The single point insulin sensitivity estimator (SPISE) is a recently developed fasting index for insulin sensitivity based on triglycerides, high density lipoprotein cholesterol, and body mass index. SPISE has been validated in juveniles and adults; still, its role during childhood remains unclear. To evaluate the age- and sex-specific distribution of SPISE, its correlation with established fasting indexes and its application as a prognostic marker for future dysglycemia during childhood and adolescence were assessed. We performed linear modeling and correlation analyses on a cross-sectional cohort of 2107 children and adolescents (age 5 to 18.4 years) with overweight or obesity. Furthermore, survival analyses were conducted upon a longitudinal cohort of 591 children with overweight/obesity (1712 observations) with a maximum follow-up time of nearly 20 years, targeting prediabetes/dysglycemia as the end point. The SPISE index decreased significantly with age (−0.34 units per year, p p p < 0.05). The SPISE index is a surrogate marker for insulin resistance predicting emerging dysglycemia in children with overweight or obesity, and could, therefore, be applied to pediatric cohorts that lack direct insulin assessment.

Keywords